138 related articles for article (PubMed ID: 37740855)
1. Differential response to neoadjuvant endocrine therapy for Black/African American and White women in NCDB.
Jones V; Schroeder MC; Roberson ML; De Andrade J; Lizarraga IM
Breast Cancer Res Treat; 2024 Jan; 203(1):125-134. PubMed ID: 37740855
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer-An NCDB Analysis (2004-2016).
Goldbach MM; Burkbauer L; Bharani T; Williams AD; Keele L; Rothman J; Jankowitz R; Tchou JC
Ann Surg Oncol; 2021 Dec; 28(13):8651-8662. PubMed ID: 34125350
[TBL] [Abstract][Full Text] [Related]
3. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
4. Racial and Ethnic Disparity in Preoperative Chemosensitivity and Survival in Patients With Early-Stage Breast Cancer.
Roy AM; Patel A; Catalfamo K; Attwood K; Khoury T; Yao S; Gandhi S
JAMA Netw Open; 2023 Nov; 6(11):e2344517. PubMed ID: 37991763
[TBL] [Abstract][Full Text] [Related]
5. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States.
Pariser AC; Sedghi T; Soulos PR; Killelea B; Gross CP; Mougalian SS
Breast Cancer Res Treat; 2019 Nov; 178(2):419-426. PubMed ID: 31401686
[TBL] [Abstract][Full Text] [Related]
6. African American women with advanced-stage ovarian cancer have worse outcomes regardless of treatment type.
Whitmore G; Ramzan A; Sheeder J; Guntupalli SR
Int J Gynecol Cancer; 2020 Jul; 30(7):1018-1025. PubMed ID: 32107316
[TBL] [Abstract][Full Text] [Related]
7. Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
Chambers LM; Jia X; Rose PG; AlHilli M
Gynecol Oncol; 2021 Feb; 160(2):405-412. PubMed ID: 33221023
[TBL] [Abstract][Full Text] [Related]
8. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity.
Zhang J; Lu CY; Chen HM; Wu SY
JAMA Netw Open; 2021 Mar; 4(3):e211785. PubMed ID: 33710293
[TBL] [Abstract][Full Text] [Related]
12. Disparities in breast cancer: a multi-institutional comparative analysis focusing on American Hispanics.
Nahleh Z; Otoukesh S; Mirshahidi HR; Nguyen AL; Nagaraj G; Botrus G; Badri N; Diab N; Alvarado A; Sanchez LA; Dwivedi AK
Cancer Med; 2018 Jun; 7(6):2710-2717. PubMed ID: 29733543
[TBL] [Abstract][Full Text] [Related]
13. Racial Differences in Response to Neoadjuvant Chemotherapy: Impact on Breast and Axillary Surgical Management.
Relation T; Obeng-Gyasi S; Bhattacharyya O; Li Y; Eskander MF; Tsung A; Oppong BA
Ann Surg Oncol; 2021 Oct; 28(11):6489-6497. PubMed ID: 33586065
[TBL] [Abstract][Full Text] [Related]
14. Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.
Livingston-Rosanoff D; Schumacher J; Vande Walle K; Stankowski-Drengler T; Greenberg CC; Neuman H; Wilke LG
Clin Breast Cancer; 2019 Dec; 19(6):e741-e747. PubMed ID: 31300338
[TBL] [Abstract][Full Text] [Related]
15. Axillary Response in Patients Undergoing Neoadjuvant Endocrine Treatment for Node-Positive Breast Cancer: Systematic Literature Review and NCDB Analysis.
Stafford A; Williams A; Edmiston K; Cocilovo C; Cohen R; Bruce S; Yoon-Flannery K; De La Cruz L
Ann Surg Oncol; 2020 Nov; 27(12):4669-4677. PubMed ID: 32909130
[TBL] [Abstract][Full Text] [Related]
16. Black/white differences in treatment and survival among women with stage IIIB-IV breast cancer at diagnosis: a US population-based study.
Enewold L; Penn DC; Stevens JL; Harlan LC
Cancer Causes Control; 2018 Jul; 29(7):657-665. PubMed ID: 29860614
[TBL] [Abstract][Full Text] [Related]
17. Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.
Chiba A; Hoskin TL; Heins CN; Hunt KK; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Feb; 24(2):418-424. PubMed ID: 27663568
[TBL] [Abstract][Full Text] [Related]
18. Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.
Tichy JR; Deal AM; Anders CK; Reeder-Hayes K; Carey LA
Breast Cancer Res Treat; 2015 Apr; 150(3):667-74. PubMed ID: 25814053
[TBL] [Abstract][Full Text] [Related]
19. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB.
Liu J; Mao K; Jiang S; Jiang W; Chen K; Kim BY; Liu Q; Jacobs LK
Oncotarget; 2016 Apr; 7(17):24848-59. PubMed ID: 26709538
[TBL] [Abstract][Full Text] [Related]
20. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer.
Hershman D; Weinberg M; Rosner Z; Alexis K; Tiersten A; Grann VR; Troxel A; Neugut AI
J Natl Cancer Inst; 2003 Oct; 95(20):1545-8. PubMed ID: 14559877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
